Facials, weight loss, aesthetics etc
This program is not available in all 50 states An account may be obligated to report information concerning this program to third parties including, but not limited to, Medicare, Medicaid, and other federal and state healthcare programs, if applicable
If treatment is discontinued, clinical evidence from the SURMOUNT-4 trial shows that appetite typically returns and partial weight regain occurs, highlighting the importance of continued therapy for sustained effects
The most optimistic approval timeline points to late the following year, with commercial availability potentially in the year after that
And in 2021, treatment for obesity (with the higher dose Wegovy) joined the list